A Phase 3 interventional study of Fibrin Sealant Grifols and EVICEL in Excessive Bleeding During Surgery, sponsored by Instituto Grifols, S.A.. Completed at 40 sites in 10 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2023-04-14.
Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).
This is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during surgery. Approximately 172 pediatric participants will be enrolled and will be randomly allocated in a 1:1 ratio into 1 of 2 treatment groups: FS Grifols or EVICEL. Enrollment will be monitored by surgery type to ensure at least 50% of the surgical procedures are hepatic.
A specific bleeding site will be defined as the TBS when it is determined by the investigator (the surgeon) that control of bleeding by conventional surgical techniques (including suture, ligature, and cautery) is ineffective or impractical and requires an adjunct treatment to achieve hemostasis.
When the TBS is identified, the investigator will record the precise anatomical location of the TBS, rate the intensity of the bleeding at the TBS (Grade 1-4 according to a 5-point validated bleeding severity scale), and record the size of the approximate bleeding surface, (small, medium, and large). For soft tissue surgery only, the investigator will also record the type of soft tissue (ie, fat, muscle, or connective tissue). In this clinical trial, only participants with a TBS with bleeding of Grade 1 (mild) or Grade 2 (moderate) intensity will be enrolled.
This study includes a Screening Visit to determine participant eligibility, a Baseline Visit, the Surgical Procedure (Day 1), and Post-operative assessments at Days 1, 4, and 30. The total duration of a participant's participation in this study is expected to be no longer than 2 months from the Screening Visit to the Post-operative Day 30 Visit.
Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pre-operative:
Participant and/or participant's legal guardian is willing to give permission for the participant to participate in the clinical trial and provide written for the participant. In addition, assent must be obtained from pediatric participants who possess the intellectual and emotional ability to comprehend the concepts involved in the clinical trial.
Intra-operative:
Exclusion Criteria:
Pre-operative:
Currently participating, or during the study is planned to participate, in any other investigational device or medicinal product study without prior and explicit approval from the sponsor.
Intra-operative:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants topically applied FS Grifols, which consisted of component 1: human fibrinogen (80 mg/mL) and component 2: human thrombin with calcium chloride (500 IU/mL) solutions filled in syringes and assembled on a syringe holder.
Biological: Fibrin Sealant Grifols
Participants topically applied EVICEL, which consisted of component 1: Concentrate of human fibrinogen (BAC 2) (55-85 mg/mL) and component 2: human thrombin (800-1200 IU/mL) solutions. The 2 components (BAC2 and thrombin) were mixed and applied topically.
Biological: EVICEL
The FE Grifols solution was applied topically via drip or spray application.
Also known as: FS Grifols
Drug pages: Fibrinogen · Thrombin
The EVICEL solution was applied topically via drip or spray application.
Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)
Hemostasis is defined as Grade 0 bleeding per 5-point validated bleeding severity scale (0=no bleeding and 4=Unidentified or inaccessible spurting or gush) at the target bleeding site (TBS) according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin.
Time frame: From start of treatment until 4 minutes after treatment start (Day 1)
Cumulative Percentage of Participants Achieving Hemostasis at the TBS by the 7 Minutes After Treatment Start (T7)
Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T7 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.
Time frame: From start of treatment to 7 minutes after start of treatment (Day 1)
Cumulative Percentage of Participants Achieving Hemostasis at the Target Bleeding Site by 10 Minutes After Treatment Start (T10)
Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T10 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.
Time frame: From start of treatment to 10 minutes after start of treatment (Day 1)
Percentage of Participants With Treatment Failures
Participants were considered treatment failures if there is a. persistent bleeding at the TBS beyond T4 b. Grade 3 or Grade 4 breakthrough bleeding from the TBS that jeopardizes participant safety according to the investigator's judgment at any moment during the 10-minute observational period and until TClosure c. Use of alternative hemostatic treatments or maneuvers (other than the study treatment) at the TBS during the 10-minute observational period and until TClosure, or use of study treatment at the TBS beyond T4 and until TClosure d. Rebleeding (Grade ≥1) at the TBS after the assessment of the primary efficacy endpoint at T4 and until TClosure.
Time frame: From start of treatment to 10 minutes after start of treatment and until the time of completion of surgical closure (Day 1)
Participants took part in the study at 18 sites in the United States, Bulgaria, France, Hungary, Romania, Serbia, and United Kingdom, from 18 January 2019 (first participant enrolled to receive the study drug) to 20 May 2022 (last participant completed).
| Milestone | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Started | 95 | 91 |
| Parenchymous surgery | 46 | 43 |
| Soft tissue surgery | 45 | 44 |
| Safety population | 91 | 87 |
| Completed | 87 | 84 |
| Not completed | 8 | 7 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Consent withdrawn by participant | 0 | 1 |
| Withdrew: Screen failure | 3 | 1 |
| Withdrew: Reason not specified | 1 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
Hemostasis is defined as Grade 0 bleeding per 5-point validated bleeding severity scale (0=no bleeding and 4=Unidentified or inaccessible spurting or gush) at the target bleeding site (TBS) according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin.
| percentage of participants | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Parenchymous Surgery | 100.0 | 100.0 |
| Soft Tissue Surgery | 93.3 | 90.9 |
Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T7 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.
| percentage of participants | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Parenchymous Surgery | 100.0 | 100.0 |
| Soft Tissue Surgery | 100.0 | 100.0 |
Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T10 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.
| percentage of participants | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Parenchymous Surgery | 97.8 | 100.0 |
| Soft Tissue Surgery | 100.0 | 100.0 |
Participants were considered treatment failures if there is a. persistent bleeding at the TBS beyond T4 b. Grade 3 or Grade 4 breakthrough bleeding from the TBS that jeopardizes participant safety according to the investigator's judgment at any moment during the 10-minute observational period and until TClosure c. Use of alternative hemostatic treatments or maneuvers (other than the study treatment) at the TBS during the 10-minute observational period and until TClosure, or use of study treatment at the TBS beyond T4 and until TClosure d. Rebleeding (Grade ≥1) at the TBS after the assessment of the primary efficacy endpoint at T4 and until TClosure.
| percentage of participants | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Parenchymous Surgery | 0 | 0 |
| Soft Tissue Surgery | 0 | 0 |
Collected over From signing informed consent form up to 7 days post study completion (Up to approximately 47 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fibrin Sealant Grifols | 1/91 (1.1%) | 8/91 (8.8%) | 20/91 (22%) |
| EVICEL | 2/87 (2.3%) | 9/87 (10.3%) | 13/87 (14.9%) |
| Event | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| Anaphylactic shockImmune system disorders | 2/91 | 0/87 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/91 | 1/87 |
| Cardiac arrestCardiac disorders | 1/91 | 1/87 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/91 | 1/87 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/91 | 1/87 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/91 | 1/87 |
| PancytopeniaBlood and lymphatic system disorders | 0/91 | 1/87 |
| AscitesGastrointestinal disorders | 0/91 | 1/87 |
| Ileus paralyticGastrointestinal disorders | 0/91 | 1/87 |
| Respiratory syncytial virus infectionInfections and infestations | 0/91 | 1/87 |
| Event | Fibrin Sealant Grifols | EVICEL |
|---|---|---|
| PyrexiaGeneral disorders | 0/91 | 5/87 |
| VomitingGastrointestinal disorders | 5/91 | 3/87 |
| AnaemiaBlood and lymphatic system disorders | 2/91 | 3/87 |
| NauseaGastrointestinal disorders | 1/91 | 2/87 |
| HypertensionVascular disorders | 2/91 | 0/87 |
| Wound dehiscenceInjury, poisoning and procedural complications | 2/91 | 0/87 |
| Abdominal distensionGastrointestinal disorders | 2/91 | 0/87 |
| Mechanical ventilation complicationInjury, poisoning and procedural complications | 0/91 | 1/87 |
| Haemoglobin decreasedInvestigations | 1/91 | 1/87 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/91 | 1/87 |
Intent-to-Treat (ITT) population included all participants who were randomized, regardless of meeting intra-operative enrollment criteria and regardless of whether the IP was administered to the participant.
| Age, Continuous(years) | Fibrin Sealant Grifols | EVICEL | Total |
|---|---|---|---|
| Mean | 8.43 ± 6.108 | 8.84 ± 6.320 | 8.63 ± 6.199 |
| Sex: Female, Male(Participants) | Fibrin Sealant Grifols | EVICEL | Total |
|---|---|---|---|
| Female | 40 | 30 | 70 |
| Male | 55 | 61 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Fibrin Sealant Grifols | EVICEL | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 11 | 24 |
| Not Hispanic or Latino | 82 | 80 | 162 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Fibrin Sealant Grifols | EVICEL | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 2 | 8 |
| White | 86 | 89 | 175 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Apr 2022, 38 months.
Results were first posted in Apr 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.